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AbstrACt
Objective Percutaneous coronary intervention (PCI) has 
seen substantial shifts in patient selection in recent years 
that have increased baseline patient mortality risk. It is 
unclear to what extent observed changes in mortality are 
attributable to background mortality risk or the indication 
and selection for PCI itself. PCI-attributable mortality 
can be estimated using relative survival, which adjusts 
observed mortality by that seen in a matched control 
population. We report relative survival ratios and compare 
these across different time periods.
Methods National Health Service PCI activity in England 
and Wales from 2007 to 2014 is considered using data 
from the British Cardiovascular Intervention Society PCI 
Registry. Background mortality is as reported in Office for 
National Statistics life tables. Relative survival ratios up 
to 1 year are estimated, matching on patient age, sex and 
procedure date. Estimates are stratified by indication for 
PCI, sex and procedure date.
results 549 305 procedures were studied after 
exclusions for missing age, sex, indication and mortality 
status. Comparing from 2007 to 2008 to 2013–2014, 
differences in crude survival at 1 year were consistently 
lower in later years across all strata. For relative survival, 
these differences remained but were smaller, suggesting 
poorer survival in later years is partly due to demographic 
characteristics. Relative survival was higher in older 
patients.
Conclusions Changes in patient demographics account 
for some but not all of the crude survival changes seen 
during the study period. Relative survival is an under-used 
methodology in interventional settings like PCI and should 
be considered wherever survival is compared between 
populations with different demographic characteristics, 
such as between countries or time periods.
IntrOduCtIOn
The worldwide use of percutaneous coronary 
intervention (PCI) for coronary revascularisa-
tion has expanded in recent years,1–6 though 
differences in this change have been observed 
internationally.7 8 In the UK, the number of 
procedures increased from around 78 000 in 
2007 to 97 000 in 2016, with the proportion 
of acute coronary syndrome (ACS) cases 
increasing from 53.6% to 64.3%9 in the same 
period. In the USA, data from the CathPCI 
registry indicate an increase in the propor-
tion of PCIs for ACS from 57.0% to 64.3% 
from 2011 to 2014.3 10
Correspondingly, patient case mix has also 
changed such that PCI is now more likely 
to be performed in older, more comorbid 
patients at higher risk of early mortality. For 
instance, in the UK between 2007 and 2015, 
mean patient age increased from 63.6 to 65.1 
years and the proportion of patients with 
diabetes rose from 17.5% to 22.0%.9 This is 
due, in part, to more permissive patient selec-
tion criteria and a move to more emergent 
indications where there is less scope for case 
selection and increased access,11 12 though 
changes in the characteristics of the general 
population may partially explain this tran-
sition. Indeed, improvements in secondary 
prevention for cardiovascular disease and 
wider societal changes in general may be 
a significant driver of changes to baseline 
patient risk given a persistent, although 
slowing, decline in age-standardised cardio-
vascular mortality in both the UK13 and 
the USA.14 In addition, the evidence-base 
strengths and limitations of this study
 ► Using national registry data, this study is the first to 
compare patient survival after percutaneous coro-
nary intervention with matched population survival 
across an entire healthcare system.
 ► It provides a template for similar investigations in 
other interventional settings where relative survival 
is under-used.
 ► Demographic matching in addition to age, sex and 
year of procedure was not possible, though life ta-
bles stratified by other characteristics may be avail-
able from the Office for National Statistics in future.
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concerning optimal intervention techniques and treat-
ment strategies has evolved, prompting changes to proce-
dural practice towards the treatment of more complex 
disease.15–17
Mortality rates following PCI will be affected by these 
trends, though it is unclear to what extent the any 
changes are related to the baseline mortality risk of 
selected patients or procedural practice. Consequently, 
there is a need to report mortality rates from national PCI 
registries within the context of the changing PCI patient 
demographic, relative to corresponding changes in the 
background population.
Relative survival is a statistical technique that compares 
the survival of a disease or treatment group with the 
survival of the general population matched on one or 
more characteristics, such as age and sex, for example 
as presented in national life-expectancy tables.18 19 The 
excess mortality—that is, the mortality after adjusting 
for the expected mortality estimated from the control 
population— associated with that group can then be 
quantified. Relative survival methods are typically used to 
study survival differences following disease diagnosis or 
to compare long-term treatment strategies where excess 
mortality develops slowly, for example in cancer.20 21 
More recently, it is being considered in cardiovascular 
settings,22–24 including PCI,25–29 though these have focused 
on long-term survival and did not consider changes over 
time.
We aimed to compare mortality rates following PCI 
with age-matched and sex-matched mortality rates found 
nationally and to examine if these comparisons differ 
between early or contemporary cohorts.
MethOds
PCI procedure data
The British Cardiovascular Intervention Society (BCIS) 
audits all PCI activity in the UK, with data collection 
managed by the National Institute for Cardiovascular 
Outcomes Research (NICOR). Information on each 
procedure is captured locally by hospitals and uploaded 
to a central server. Mortality tracking is available via the 
Office for National Statistics (ONS) for procedures in 
England and Wales for patients with a valid National 
Health Service number. Mortality tracking was available 
up to May 2015.
Procedures in England and Wales between 2007 and 
2014 for patients aged between 18 and 100 years old were 
extracted. Procedures with missing age, sex, indication 
and mortality status were excluded.
Ons life-table data
Expected mortality rates for England and Wales are avail-
able from ONS national life-tables stratified by age in 
1 year bands, se, and calendar year.30
statistical analysis
Each procedure was matched to expected mortality life-
table data based on the patients’ age, sex and the date 
of the procedure. Survival models were stratified by 
procedure date (2007–2008, 2009–2010, 2011–2012, 
2013–2014), and by patient sex and indication (elective, 
unstable angina or non-ST-elevation myocardial infarc-
tion (UA/NSTEMI), ST-elevation myocardial infarction 
(STEMI)) as these are known determinants of survival, 
and there are distinct survival differences between these 
groups. Two-year time periods were chosen to ensure 
temporal trends are sufficiently captured while main-
taining clarity of exposition. Analyses consider mortality 
up to 1 year postprocedure with mortality censored 
thereafter, as long-term estimates are confounded by 
the increasing influence of competing contributors to 
mortality and time-varying risk factors.31
Crude survival rates are plotted, with survival differences 
between periods compared using the log-rank test.32 33 
Relative survival models are built that adjust for expected 
survival using the Ederer II method.18 19 Relative survival 
estimates are plotted, and differences between periods 
compared using the log-rank test after a transformation 
of survival time described by Stare et al.34 The observed 
(PCI) and expected (life-table) 1-year mortality rates are 
also compared by considering their ratios across different 
ages. This expresses the relationship of relative survival 
and age without explicitly modelling the hazard function, 
which is challenging in this setting since the hazard falls 
extremely steeply in the early stages of follow-up. This 
quantity is plotted, using general additive models with a 
binomial link to smooth observed mortality.
The relative survival estimate, calculable at each day 
postprocedure, is the ratio of the observed survival 
proportion of those who had PCI to the expected survival 
proportion based on a matched population. This quan-
tity can interpreted as the post-PCI survival rate if patients 
were only exposed to PCI-related mortality risk and not 
other background risks. PCI-related mortality risk should 
be understood as the mortality risk of being a person who 
had PCI, not simply the risk of the procedure itself. If the 
relative survival estimate levels-off after a given time then, 
on average, there is no additional PCI-related mortality 
risk for those who survived up to that time. If the relative 
survival estimate increases then, on average, mortality was 
less than expected had the patients not needed PCI. In 
most interventional settings, this quantity is typically less 
than one, indicating that PCI is associated with a greater 
mortality risk than no PCI.
All analyses were performed using R V.3.4.4.35 The 
tidyverse data manipulation and visualisation suite36 was 
used throughout. The relsurv package37–39 was used for 
relative survival modelling. The complete R script is avail-
able on GitHub,40 with synthetic BCIS data provided to 
replicate analysis steps without disclosing proprietary 
BCIS data. Access to study materials was only required for 
the first author.
Patient involvement
This is a registry-based study with all data collected prior 
to the design phase and outcomes necessarily restricted 
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to mortality only. Therefore, patients were not involved in 
the design of this study.
results
In total, there were 575 203 procedures recorded in the 
BCIS-NICOR registry between 2007 and 2014 in England 
and Wales, of which 549 305 (95.5%) were available for 
analysis after exclusions due to missing data (see online 
supplementary table A1). Follow-up is complete for every 
procedure up to 1 year (ie, no censoring occurred before 
1 year), except for procedures from June to December 
2014, where available follow-up time was less than 1 year.
Table 1 presents procedure numbers by year, sex and 
indication, and online supplementary table A2a-c present 
baseline patient characteristics and mortality rates for 
elective, UA/NSTEMI and STEMI procedures, respec-
tively. Female patients made up a quarter (25.9%) of 
procedures. Mean patient age increased from 63.8 years 
old in 2007–2008 to 65.1 years old in 2013–2014, with 
similar increases observed within indications (64.5 to 
65.8 years for elective procedures; 63.6 to 65.7 years for 
UA/NSTEMI; 62.1 to 63.5 years for STEMI). PCI for ACS 
(UA/NSTEMI/STEMI) accounted for 61.5% of proce-
dures though this proportion increased from 54.0% to 
65.7%.
Figure 1 presents the observed survival rates without 
adjustment for expected survival. Across all indica-
tions mortality risk is highest immediately following the 
procedures as this is where the survival curve gradient is 
steepest. The log-rank test indicates some differences in 
crude survival rates between periods and, typically, more 
recent years are associated with lower survival. Survival 
differences by indication and sex are also evident, with 
survival consistently lower in women. Comparing crude 
survival from 2007 to2008 to 2013–2014 at 1 year: elective 
procedures, 97.7% to 97.5% for women and 98.0% vs 
97.7% for men; UA/STEMI, 94.6% vs 93.7% for women 
and 95.8% vs 94.4% for men; STEMI, 87.5% vs 86.4% for 
Table 1 Number of procedures by period, sex, indication
2007–2008 2009–2010 2011–2012 2013–2014 2007–2014
N % N % N % N % N %
Female
  Elective 13 847 45.2 13 392 38.4 12 603 33.0 12 093 31.3 51 935 36.5
  UA/NSTEMI 12 756 41.6 13 858 39.8 15 139 39.6 15 594 40.4 57 347 40.3
  STEMI 4043 13.2 7608 21.8 10 480 27.4 10 908 28.3 33 039 23.2
  Total 30 646 34 858 38 222 38 595 142 321
Male
  Elective 40 246 46.3 40 284 40.4 39 715 36.3 39 228 35.3 159 473 39.2
  UA/NSTEMI 33 797 38.9 37 049 37.2 39 379 36.0 40 749 36.7 150 974 37.1
  STEMI 12 921 14.9 22 306 22.4 30 244 27.7 31 066 28.0 96 537 23.7
  Total 86 964 99 639 109 338 111 043 406 984
Male and female
  Elective 54 093 46.0 53 676 39.9 52 318 35.5 51 321 34.3 211 408 38.5
  UA/NSTEMI 46 505 39.6 50 745 37.8 54 314 36.9 56 152 37.7 208 321 37.9
  STEMI 16 964 14.4 29 914 22.2 40 724 27.6 41 974 28.1 129 576 23.6
  Total 117 610 134 497 147 560 149 638 549 305
Figure 1 Observed survival rates by patient indication and 
year of procedure. P values are from the log-rank test.
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women and 92.0% vs 91.3% for men (see online supple-
mentary table A2).
Figure 2 shows the relative survival estimate. For elective 
procedures relative survival levels-off quickly, indicating 
that procedural mortality risk is present immediately 
following the procedure but that on average, risk returns 
to the matched population baseline. For ACS procedures, 
relative survival continues to decline up to 1-year postpro-
cedure, indicating long-term excess risk in these patients 
compared with the matched population. The log-rank test 
for relative survival differences reveals smaller differences 
than for crude survival, though there remains strong 
evidence of survival differences for men following PCI for 
UA/STEMI or STEMI. Comparing relative survival from 
2007 to 2008 to 2013–2014 at 1 year: elective procedures, 
99.5% to 99.5% for women and 100% vs 99.8% for men; 
UA/STEMI, 96.7% vs 96.1% for women and 97.8% vs 
96.6% for men; STEMI, 89.5% vs 88.6% for women and 
93.6% vs 93.0% for men (see online supplementary table 
A3).
Figure 3 shows the ratio between observed and expected 
1 year mortality rates by patient age. For younger patients, 
observed mortality is considerably higher than expected 
mortality, but this gap reduces with patient age. For 
instance, observed mortality at 1 year following elective 
PCI is 2–5 times greater than expected at age 50, but 
these are equal by age 80. For UA/NSTEMI, this ratio is 
between 5 and 10 at age 50, though is less than 3 by age 
80. For STEMI, this ratio decreases from around 9–15 to 
around 5 from age 50 to 80. There are no clear trends 
over time.
Confidence intervals at the 95% level for figures 1–3 
are provided in supplementary materials (online supple-
mentary figure A1-3), as are plots of the cumulative excess 
hazard rate (online supplementary figure A4), which 
may be interpreted as the total additional exposure to 
mortality risk at any point in time for patients with PCI 
compared with the general population.
dIsCussIOn
We present results for 549 305 PCI procedures over an 
8-year period showing observed, expected and relative 
survival estimates over time. We demonstrate that, after 
adjustment for patient age, sex and procedure date using 
national life-table mortality rates, differences in patient 
survival over time are present in men following PCI for 
ACS, though these differences are small (relative survival 
at 1 year: UA/NSTEMI 97.8% in 2007–2008 vs 96.6% 
in 2013–2014; STEMI 93.6% in 2007–2008 vs 93.0% in 
Figure 2 Relative survival estimates by patient indication 
and year of procedure. P values are from a log-rank-type test 
for relative survival curves.
Figure 3 Observed-to-expected 1-year mortality ratio (log-
scale) by patient age. Binomial general additive models with 
7-knot splines are used for smoothing the observed 1-year 
mortality, then divided by the expected mortality rate. 95% 
confidence limits are removed for clarity.
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2013–2014). Small, non-significant relative survival differ-
ences were found within other strata. However, the poten-
tial counteracting effects of selection factors (that may 
have increased mortality risk) and of improvements in 
processes of care (that may have reduced mortality risk) 
cannot be ruled out.
For elective cases, there is evidence that relative 
survival increases after the initial postprocedural risk. 
This suggests that, conditional on surviving the initial 
risk shock, mortality is on average lower than in the 
matched population. This is likely driven by patient selec-
tion factors, particularly for more elderly patients, where 
there may be selection bias such that PCI is undertaken 
in only the healthiest patients. Another factor may be 
that these patients are highly likely to be supported with 
secondary prevention treatments for coronary artery 
disease, whereas in the general population, there may 
be many people with undetected or untreated coronary 
artery disease (CAD).
Mortality increases with age at a rate that is lower 
in the PCI population than in an equivalent matched 
population. In other words, though mortality is natu-
rally higher as age increases, older patients treated by 
PCI have a mortality rate more similar to the rate in the 
general population than younger patients. This is true 
across all indications. In general then, relative survival 
is higher for older patients compared with younger 
patients, though in absolute terms their prognosis is still 
poorer.
This may partly be determined by clinician selection 
practices, such that younger patients with CAD are more 
likely to be referred for PCI than older patients for whom 
PCI is not optimal. For instance, any 80-year-old consid-
ered well enough to undergo elective PCI is likely to have 
fewer comorbidities and frailties compared with other 
80-year-old on average. Equally, epidemiological selec-
tion suggests that a 40-year-old requiring elective PCI will 
undoubtedly have a higher baseline risk for mortality than 
the average 40-year-old since the prevalence of cardiovas-
cular disease is low at this age. For urgent or emergency 
procedures, simply being part of the PCI registry suggests 
a degree of patient resilience having experienced an 
acute, life-threatening event yet survived long enough to 
be treated. At the onset of an ACS, as older patients are 
more likely than younger patients to die before receiving 
PCI or any other treatment, those older patients that 
do receive PCI will typically be less frail than others of a 
similar age. The distinct trend for higher relative survival 
in older patients is thus clear evidence of these selection 
processes at play, and demonstrates the importance of 
accounting for these imbalances when analysing registry 
data.
Across all indications, both absolute and relative 
survival is lower in women than in men. This is a well-
known phenomenon in cardiovascular settings variously 
attributed to differences in age, comorbidities, time 
to treatment and secondary prevention.41–44 This work 
demonstrates unequivocally that differences in age and 
background mortality rates do not sufficiently account for 
this disparity.
In general, both crude and relative survival estimates are 
lower in recent years. Assuming a consistent data collec-
tion methodology over time, realistically this can either be 
attributed to an average reduction in procedural efficacy 
or an increase in higher risk procedures that is not solely 
explained by age-adjusted and sex-adjusted background 
mortality. In the context of rapid changes to PCI patient 
case mix and practice in recent years,45 including more 
permissive patient selection criteria and increasing use of 
PCI in favour of alternative revascularisation strategies, 
the small decline in relative survival observed from 2007 
to 2014 is unsurprising. Further adjustment for patient 
case mix will demonstrate if and where actual survival 
gains have been made, or indeed if survival in certain 
groups of patients has not improved over time.
Relative survival offers distinct advantages over crude 
survival rates.19 The relative mortality estimate (one 
minus relative survival) may be interpreted as an approx-
imation of the excess mortality attributable jointly to the 
indication for intervention and the intervention itself. 
This allows PCI-specific mortality to be measured without 
needing cause of death information which may often be 
inconsistently recorded or unavailable completely. Rela-
tive survival also conveniently accounts for mortality that 
may be only indirectly related to PCI, for instance non-car-
diac mortality secondary to postoperative bleeding.
As the underlying population may vary consider-
ably across different countries, intervention registries 
or time periods, methods that appropriately adjust for 
background population mortality provide more suit-
able survival estimates for comparison in time and space 
than crude survival alone, provided the comparisons 
are valid.46 47 However, despite the popularity of relative 
survival methodology to compare survival in diseased 
versus non-diseased populations, in particular cancer, 
these methods have only recently seen some use in inter-
ventional settings like PCI, and relative survival is not 
routinely reported by PCI registries. This study concisely 
demonstrates the feasibility and appropriateness of the 
relative survival approach in such settings and provides 
a useful template for producing population-adjusted PCI 
survival estimates in the future.
limitations
Patients are matched to national mortality estimates by 
year, age and sex only. Despite stratification of models by 
these factors, substantial case heterogeneity will remain 
that is not modelled. No account is taken for other poten-
tially unbalanced factors such as ethnicity, socialeconomic 
status and comorbidities. Accounting for these factors is 
not possible with the simple relative survival approach 
used here as national life-tables stratifying by these factors 
are not readily available. However, using regression 
modelling in this setting is challenging as the mortality 
risk following PCI is raised acutely and the hazard rate 
changes rapidly; modelling the hazard must be done with 
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extreme care as many assumptions of standard regression 
techniques are unlikely to hold.
Patients will be present more than once in the PCI 
cohorts if they have been readmitted for subsequent PCI 
within the study period. The proportion of procedures in 
patients already present in the cohort is 13.5%, though 
this is reduced to 7.3% when considering indications 
separately.
Life-table data is based on national mortality statis-
tics and therefore is not strictly independent of the PCI 
registry, since all patients will contribute to population 
and mortality statistics. This is an unavoidable complica-
tion in the absence of stratification by CAD or PCI status 
that biases results towards no relative survival difference. 
However, given the analysis cohort constitutes less than 
1% of the population of England and Wales, this bias can 
be considered negligible.
As the log-rank tests stratify groups independently it 
will ignore the inherent correlation between adjacent or 
near-adjacent years. It does not provide point estimates 
of differences between strata as all differences through 
time contribute to the test statistic. It is therefore most 
useful when used alongside a graphical representation of 
survival differences.
COnClusIOn
We demonstrate that the decline in indication-strati-
fied crude survival rate over time is less apparent after 
adjusting for expected population mortality matched 
on age, sex and procedure year, though patient demo-
graphics do not explain all of the difference. Adjusting 
for additional patient risk factors is necessary to identify 
other drivers of mortality change.
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